Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and benefit of risperidone for the
treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly
used in clinical practice to treat chorea, however, it has not been approved by the Food and
Drug Administration (FDA) to treat chorea. This study will examine 1) whether the
investigators see MRI changes with risperidone treatment and 2) whether sensors applied to
the participants body can measure chorea and detect changes in chorea.